Froehner M. Re: Armstrong AJ, Petrylak DP, Shore ND, et al. ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.12.02 Eur Urol 2026 Aug 7:S0302-2838(26)02161-5. doi: 10.1016/j.eururo.2026.
PMID: 42567750